Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
NCT00725764
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
14
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms, Head and Neck
Interventions
DRUG:
GSK1363089 (foretinib)
Sponsor
GlaxoSmithKline